Turmeric for Blood Sugar and Type 2 Diabetes

Table of Contents

1. What the Blood Sugar Numbers Actually Mean
2. Insulin Resistance, Explained Without Jargon
3. The Headline Trial: Chuengsamarn 2012
4. Why One Remarkable Trial Is Not Settled Science
5. The Follow-Up: Atherogenic Risk in Established Diabetes
6. The 2024 Trial in Obesity and Type 2 Diabetes
7. What the Meta-Analyses Find
8. Curcumin Plus Piperine
9. Weight, BMI and Waist Circumference
10. This Is Not a Replacement for Metformin
11. If You Decide to Try It Anyway
12. Cautions
13. Key Research Papers
14. Connections
15. Featured Videos

What the Blood Sugar Numbers Actually Mean

Three numbers dominate every trial on this page, and it is worth knowing what each one is before you read results built on them.

Fasting blood glucose is a single snapshot taken after eight hours without food. It tells you where your blood sugar sits at its quietest. It is cheap, fast and noisy — a bad night's sleep, an infection or a stressful morning can shift it. In most systems, below about 100 mg/dL is normal, 100–125 mg/dL is the prediabetes range, and 126 mg/dL or above on two occasions is diabetes.

HbA1c is the far more useful measure, and the one worth understanding properly. Haemoglobin is the protein in red blood cells that carries oxygen. Glucose in the bloodstream sticks to it slowly and irreversibly — a chemical process called glycation, and the same reaction that browns a roast. Because a red blood cell lives about three months, the percentage of your haemoglobin that has been sugar-coated is a running average of your blood glucose over roughly the previous eight to twelve weeks. It cannot be gamed by fasting the day before the test. Below 5.7 percent is normal; 5.7–6.4 percent is prediabetes; 6.5 percent or above is diabetes.

Think of HbA1c as the odometer and fasting glucose as the speedometer. One tells you how fast you are going right now; the other tells you how far you have travelled. This is why an eight-week trial is only barely long enough to move HbA1c at all — the measure itself averages over most of that window.

Fasting insulin and HOMA-IR are the third piece. HOMA-IR is a simple calculation combining fasting glucose and fasting insulin into a single index of how hard your pancreas is working to keep your glucose where it is. Two people can have identical, perfectly normal glucose readings while one of them is producing four times as much insulin to achieve it. The one working four times harder is on a trajectory the other is not. HOMA-IR is an attempt to see that difference — it is a research tool rather than a clinical one, and it is sensitive to the same day-to-day noise as its inputs.

Back to Table of Contents

Insulin Resistance, Explained Without Jargon

Insulin is a doorman. After you eat, glucose floods the bloodstream, the pancreas releases insulin, and insulin tells muscle, fat and liver cells to open their doors and take the glucose in. In insulin resistance the doorman is shouting and the doors open slowly. The pancreas responds by shouting louder — making more insulin — and for years this works. Blood glucose stays normal. Nothing shows up on a routine test. Underneath, insulin levels are climbing.

Type 2 diabetes is what happens when that compensation fails. The beta cells of the pancreas, having worked at maximum output for a decade or two, begin to falter. Insulin production slips, the doors stay shut, and glucose starts backing up in the blood. By the time a diagnosis is made, a substantial fraction of beta-cell function is often already gone — which is why prevention during the prediabetic years is so much more valuable than treatment afterwards, and why a trial in prediabetes is more interesting than the same trial in established disease.

Why would an anti-inflammatory compound matter to any of this? Because the sticking of the doors is partly an inflammatory phenomenon. Enlarged fat cells, especially visceral fat, release inflammatory signals; those signals activate stress kinases inside muscle and liver cells; those kinases interfere with the insulin receptor's internal wiring. Chronic inflammation is one of the established mechanisms of insulin resistance, not a fringe theory. That gives curcumin a coherent route to a real effect, and it is the reason researchers went looking in the first place.

Back to Table of Contents

The Headline Trial: Chuengsamarn 2012

Somlak Chuengsamarn and colleagues at Srinakharinwirot University in Thailand designed the trial that this whole page orbits, and it deserves a proper description rather than a headline.

• Who: 240 adults who met the criteria for prediabetes — impaired fasting glucose, impaired glucose tolerance, or both. These were people on the road to diabetes but not yet there, which is exactly the population where prevention could matter most.
• What: Curcuminoid extract capsules or matching placebo, six capsules a day, each capsule standardised to 250 mg of curcuminoids — a total of 1,500 mg of curcuminoids daily. That is a substantial dose of plain extract, not a trace of culinary turmeric.
• How long: Nine months, with assessments at three, six and nine months. This is unusually long for a supplement trial and is one of the study's genuine strengths.
• The endpoint: Progression to type 2 diabetes, defined by standard diagnostic criteria. Not a marker. An actual diagnosis.

The result: nobody in the curcuminoid arm was diagnosed with type 2 diabetes over the nine months. In the placebo arm, about 16 percent were. Alongside that, the curcuminoid group showed better beta-cell function on HOMA-beta, lower C-peptide (a marker of how much insulin the pancreas is churning out), and higher adiponectin — a hormone released by healthy fat tissue that improves insulin sensitivity and falls as metabolic health deteriorates.

Taken at face value, that is a diabetes-prevention effect larger than anything achieved by lifestyle programmes or by metformin in the major prevention trials, produced by a cheap over-the-counter spice extract with no serious side effects reported. If it were straightforwardly true, it would be one of the more consequential findings in preventive medicine this century.

Back to Table of Contents

Why One Remarkable Trial Is Not Settled Science

Here is the uncomfortable part, and it matters more than the result itself.

It is a single-centre trial. One institution, one team, one country, one population, one set of procedures. Single-centre trials produce larger effects than multi-centre trials do, systematically and across all of medicine. This is not an accusation of anything; it is an observed regularity. When the same question is later asked at twenty sites by people with no stake in the answer, effects usually shrink, sometimes to nothing.

The effect size is extreme. Zero progression in the treatment arm is not a modest benefit; it is total prevention. In medicine, extreme effects from cheap, well-tolerated interventions are rare, and the base rate for such findings surviving replication is not encouraging. The strength of the result is, paradoxically, a reason for extra caution rather than extra confidence.

It has not been replicated at that scale. Fourteen years on, no independent group has run a nine-month, 240-person prediabetes prevention trial of curcuminoids and published a matching result. That absence is itself information. A finding this important should have attracted replication attempts; the diabetes-prevention field is well funded and highly competitive.

Much of the supporting work shares authors. The 2014 atherogenic-risk trial and the 2024 obesity trial described below come from overlapping Thai research groups. Related work from the same tradition is genuinely valuable, but it is not the independent confirmation that a finding of this magnitude requires.

The population may not be yours. A Thai cohort with a particular dietary background, body composition and genetic profile may respond differently from a European or North American one. Diabetes-prevention effects have varied by ethnicity in other trials.

None of this makes the trial wrong. It makes it unconfirmed. The honest position is that Chuengsamarn 2012 is the single best reason to run a large multi-centre curcumin prevention trial, and that until someone does, it remains one striking result rather than an established fact.

Back to Table of Contents

The Follow-Up: Atherogenic Risk in Established Diabetes

Two years later the same group turned to people who already had type 2 diabetes, asking a different question: not whether curcuminoids prevent diabetes, but whether they reduce the cardiovascular damage that diabetes causes. The study randomised 240 people with type 2 diabetes to curcuminoid extract or placebo for six months.

The endpoints were a cluster of atherosclerosis-related measures. Pulse wave velocity — the speed at which the pressure wave from each heartbeat travels down the aorta, and a well-validated index of arterial stiffness — improved in the curcuminoid group. So did the adipokine picture: adiponectin up, leptin down, which is the direction associated with healthier fat tissue. Insulin resistance on HOMA-IR fell, as did measures of body fat, along with improvements in the lipid panel and in uric acid.

The word "atherogenic" in the title is doing a lot of work and is worth unpacking. Atherogenic risk means the constellation of measurements that predict plaque formation in artery walls. Reducing atherogenic risk is not the same as reducing heart attacks — it is a bet that the two travel together, which they usually but not invariably do. Everything in this trial is a surrogate. Nobody counted cardiovascular events.

Pulse wave velocity is the most interesting entry on the list, because arterial stiffness is a structural property rather than a chemistry reading, and it is a strong independent predictor of cardiovascular outcomes. It is also, notably, the measure that a later, very different trial in kidney disease failed to improve — a contrast worth holding in mind and one covered on the blood vessels page.

Back to Table of Contents

The 2024 Trial in Obesity and Type 2 Diabetes

The most recent substantial trial in this line, published in Nutrients in 2024, applied the same approach to a harder population: people who were both obese and diabetic, where metabolic risk compounds. It was a randomised controlled trial with a twelve-month intervention, again reporting reductions in atherogenic risk measures — arterial stiffness, the atherogenic index of plasma, inflammatory markers and lipid fractions.

The strengths are real. Twelve months is long for this literature. The population is one where any genuine benefit would matter enormously, since obesity and type 2 diabetes together drive a disproportionate share of cardiovascular disease and kidney failure. Repeating a protocol over more than a decade with consistent findings is not nothing.

The limitation is the one already stated: this is continuation of a research programme, not independent verification of it. And once again, every endpoint is a surrogate. A twelve-month trial counting heart attacks in this population would need thousands of participants and would cost a great deal of money, which is precisely why nobody has run one.

Back to Table of Contents

What the Meta-Analyses Find

When you pool the whole published literature rather than reading the best study in it, the picture becomes considerably more ordinary — and considerably more believable.

A 2026 systematic review and dose-response meta-analysis in Food Science and Nutrition gathered the randomised trials of curcumin and turmeric supplementation in adults with prediabetes and type 2 diabetes and examined glycaemic control across them. The finding, in the direction that matters, is that supplementation is associated with improvements in fasting glucose, HbA1c and insulin resistance. The size of those improvements is modest — the kind of movement that is statistically detectable in a pooled analysis and clinically marginal in an individual, particularly next to what diet change, weight loss or a glucose-lowering drug will do.

A dose-response analysis is a useful addition, because a genuine drug effect should generally scale with dose in some describable way. A pooled result that shows no relationship between how much was given and how much changed is weaker evidence of causation than one that does.

Read these analyses with the standard cautions in mind. The trials being pooled are mostly small. They use different products at different doses with different absorption. They run for different lengths of time in different populations. Heterogeneity in such a pool is high, and high heterogeneity means the single summary number conceals more than it reveals. And small, positive, easily published trials are exactly the kind that accumulate in a literature while the null results sit in a drawer.

The fair summary: the wider evidence supports a small, real improvement in blood sugar measures, not the dramatic prevention effect of the single headline trial.

Back to Table of Contents

Curcumin Plus Piperine

Curcumin's central weakness is that almost none of it reaches your bloodstream. It dissolves poorly, degrades at intestinal pH, and is rapidly conjugated by the liver and gut wall and shipped straight back out. The classic 1998 study by Shoba and colleagues established the workaround that most products now rely on: co-administering piperine, the alkaloid that makes black pepper hot, slows that conjugation step and raises curcumin's blood levels dramatically in human volunteers.

A 2025 meta-analysis in the Journal of Diabetes and Metabolic Disorders pooled the randomised trials that used the combination and examined glycaemic control specifically. Asking about the combination separately is the right question, because a piperine-enhanced product is pharmacologically a different intervention from plain extract, and lumping the two together in one analysis blurs a real distinction.

Two practical notes. First, piperine is why traditional preparations — turmeric cooked in fat with black pepper — are more sensible than turmeric stirred into water, and the tradition long predates anyone measuring plasma concentrations. Second, piperine does not restrict its enzyme-slowing to curcumin. It can raise blood levels of prescription medicines processed by the same pathways, and the more successfully a product enhances absorption, the more seriously that interaction should be taken. Absorption-enhanced products have also featured prominently in the reported cases of turmeric-associated liver injury.

Back to Table of Contents

Weight, BMI and Waist Circumference

Body weight is entangled with blood sugar at every point, so a 2026 meta-analysis in Nutrition Reviews asked a narrow, useful question: does curcumin supplementation change body weight, body mass index or waist circumference in people with type 2 diabetes?

Waist circumference is the measurement to watch among the three. Body weight and BMI cannot distinguish muscle from fat, or fat under the skin from fat packed around the organs. Visceral fat — the kind that wraps the liver, pancreas and intestines — is the metabolically dangerous variety, and waist circumference is a rough but genuinely informative proxy for it. A trial that moves waist circumference without moving weight has shifted body composition, which may matter more than the scale.

Keep expectations proportionate. No supplement produces weight change comparable to a sustained change in diet, and any reduction in these measures across pooled trials will be small. If a product's marketing leads with weight loss, the marketing has outrun the evidence. The realistic framing is a modest nudge on top of the things that actually work, not a substitute for them.

Back to Table of Contents

This Is Not a Replacement for Metformin

This needs saying without hedging, because it is the specific way people get hurt by pages like this one.

Nothing on this page is a reason to stop or reduce a prescribed diabetes medication. Metformin has been studied in tens of thousands of people over decades, with hard outcome data behind it — not markers, but complications, hospitalisations and deaths. Curcumin has been studied in a few thousand people, almost entirely on markers, with no outcome trial of any size. Those two bodies of evidence are not in the same category, and no meta-analysis of surrogate endpoints closes the gap.

No trial has ever compared curcumin against metformin for preventing the things diabetes actually does to people: kidney failure, retinopathy, neuropathy, amputation, heart attack, stroke. Until such a trial exists, any comparison between the two is speculation dressed as inference.

There is also a specific danger in the other direction. If turmeric genuinely lowers blood glucose — which is the claim — then adding it to insulin or a sulfonylurea can push glucose too low. Hypoglycaemia is not a theoretical inconvenience; it causes confusion, falls, car accidents and, at the extreme, seizures. This is a reason to tell your diabetes team what you are taking and to check your levels more often for the first few weeks, not a reason to be frightened.

The honest framing is simple. Turmeric is a reasonable addition to a diet for someone working seriously on their metabolic health with their clinician. It is not a treatment, and the moment it is used as a substitute for one it becomes dangerous.

Back to Table of Contents

If You Decide to Try It Anyway

Plenty of readers will want to try it regardless, and there is nothing unreasonable about that — the risk is low, the cost is low, and the mechanism is plausible. Some practical notes.

• Tell whoever manages your diabetes. Not for permission — so that if your numbers move, everyone knows what changed and why.
• Match the trial doses if you want the trial's conditions. The Thai studies used 1,500 mg of curcuminoids a day from plain extract. Phospholipid-complexed and other enhanced-absorption products use much smaller numbers to deliver comparable exposure; those figures are not interchangeable.
• Take it with a meal containing fat. Curcumin is fat-soluble. On an empty stomach, absorption is worse.
• Give it three months before judging. HbA1c averages the previous two to three months by definition. Measuring at four weeks measures mostly the period before you started.
• Watch your own numbers, not the literature. Your fasting glucose and HbA1c before starting, and again at three and six months, are more informative about you than any meta-analysis is.
• Stop if anything looks like liver trouble. Yellowing skin or eyes, dark urine, pale stools, persistent nausea, unexplained fatigue or right-upper-abdominal pain all warrant stopping and getting liver enzymes checked.
• Do not let it become the intervention. The measures that actually move blood sugar are what you eat, how much you move, how you sleep and how much visceral fat you carry. A capsule is at best a small addition to those, and at worst a comfortable distraction from them.

Back to Table of Contents

Cautions

• Hypoglycaemia risk with glucose-lowering drugs. Particularly insulin and sulfonylureas such as glipizide or gliclazide. Monitor more closely when starting.
• Liver injury. Rare but documented, and serious when it occurs. A 2023 case series from the US Drug-Induced Liver Injury Network described ten cases linked to turmeric supplements, with absorption-enhanced products over-represented and a genetic susceptibility marker identified in many of the affected patients.
• Antiplatelet and anticoagulant interaction. Curcumin inhibits platelet aggregation in the laboratory. Anyone on warfarin, a direct oral anticoagulant, clopidogrel or daily aspirin should raise this with a prescriber.
• Piperine and prescription drugs. The mechanism that boosts curcumin absorption can boost other drugs' levels too.
• Iron absorption. Curcumin binds iron and has been implicated in worsening iron deficiency at high supplemental doses. Relevant if you are already anaemic.
• Gallbladder disease. Turmeric stimulates gallbladder contraction; avoid concentrated doses with known gallstones or biliary obstruction.
• Surgery. Stop one to two weeks beforehand and tell the surgical team, as with any supplement that affects platelets.

The fuller treatment of all of this is on the Turmeric Safety and Interactions leg.

Back to Table of Contents

Key Research Papers

1. Chuengsamarn S, Rattanamongkolgul S, Luechapudiporn R, et al. (2012). Curcumin extract for prevention of type 2 diabetes. Diabetes Care. (The nine-month Thai prediabetes trial; single-centre and not replicated at this scale.) — PubMed PMID: 22773702
2. Chuengsamarn S, Rattanamongkolgul S, Phonrat B, et al. (2014). Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract: a randomized controlled trial. Journal of Nutritional Biochemistry. — PubMed PMID: 24445038
3. Yaikwawong M, Jansarikit L, Jirawatnotai S, et al. (2024). The Effect of Curcumin on Reducing Atherogenic Risks in Obese Patients with Type 2 Diabetes: A Randomized Controlled Trial. Nutrients. — PubMed PMID: 39125322
4. Bahari H, Jazinaki MS, Asadi Z, et al. (2026). Curcumin/Turmeric Supplementation on Glycemic Control in Adults With Prediabetes and Type 2 Diabetes: A Systematic Review and Dose-Response Meta-Analysis. Food Science and Nutrition. — PubMed PMID: 42005325
5. Karimi M, Moshrefi S, Bahman AD, et al. (2025). Effect of curcumin plus piperine co-supplementation on glycemic control in adults: A meta-analysis of randomized controlled trials. Journal of Diabetes and Metabolic Disorders. — PubMed PMID: 41393198
6. Alivand N, Alivand S, Masoumi SJ, et al. (2026). The Effects of Curcumin Supplementation on Body Weight, Body Mass Index, and Waist Circumference in Patients With Type 2 Diabetes. Nutrition Reviews. — PubMed PMID: 41211694
7. Shoba G, Joy D, Joseph T, et al. (1998). Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Medica. — PubMed PMID: 9619120
8. Gupta SC, Patchva S, Aggarwal BB. (2013). Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS Journal. — PubMed PMID: 23143785
9. Nelson KM, Dahlin JL, Bisson J, et al. (2017). The Essential Medicinal Chemistry of Curcumin. Journal of Medicinal Chemistry. (A published critique arguing that curcumin's instability and poor bioavailability undermine much of the mechanistic literature.) — PubMed PMID: 28074653
10. Halegoua-DeMarzio D, Navarro V, Ahmad J, et al. (2023). Liver Injury Associated with Turmeric — A Growing Problem: Ten Cases from the Drug-Induced Liver Injury Network [DILIN]. American Journal of Medicine. — PubMed PMID: 36252717

PubMed Topic Searches

1. PubMed: Curcumin and type 2 diabetes, randomized controlled trials
2. PubMed: Curcumin and HbA1c
3. PubMed: Curcumin, insulin resistance and HOMA-IR
4. PubMed: Curcumin and prediabetes prevention
5. PubMed: Curcumin, beta-cell function and adiponectin
6. PubMed: Curcumin and diabetic kidney disease
7. PubMed: Curcumin compared with metformin
8. PubMed: Limitations of surrogate endpoints in diabetes trials

Back to Table of Contents

Connections

• Turmeric for Heart and Metabolic Health
• Turmeric and Cholesterol
• Turmeric, Blood Vessels and Blood Pressure
• Turmeric for Fatty Liver and Metabolic Syndrome
• Turmeric
• Turmeric Bioavailability and Forms
• Turmeric and Liver Health
• Turmeric Safety and Interactions
• Turmeric for Digestive Health
• Javanese Turmeric
• Black Ginger
• Culinary and Spice Herbs
• Gut Health
• All Herbs

Back to Table of Contents